3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
3
Terminated
1
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Polycystic Ovary Syndrome
7
Neoplasms
3
Melanoma
3
Urinary Bladder Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Obesity
2
Infertility
2
Glioblastoma
2
Endometrial Neoplasms
2
Breast Neoplasms
2
Adenocarcinoma Of Esophagus
2
Uterine Cervical Neoplasms
1
TP53 Y220C Mutation
1
Sarcoma, Ewing
1
Sarcoma
1
Prostate Cancer Recurrent
1
Progression-Free Survival
1
Preleukemia
1
Posterior Fossa Ependymal Tumor
1
Osteosarcoma
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms by Site
1
Metabolic Diseases
1
Medulloblastoma
1
Leukoplakia, Oral
1
Leukemia, Myeloid, Acute
1
Insulin Resistance
1
Hyperandrogenism
1
Interventions
pembrolizumab
25
Cisplatin
17
Carboplatin
13
Radiotherapy
12
Cetuximab
9
Blood Specimen Collection
9
Docetaxel
8
Paclitaxel
7
Fluorouracil
7
Drug Therapy
7
toripalimab
6
tislelizumab
4
nimotuzumab
4
atezolizumab
4
Surveys and Questionnaires
4
Radiation
4
Chemoradiotherapy
4
fludarabine
3
Surgical Procedures, Operative
3
Standard of Care
3
Radiotherapy, Intensity-Modulated
3
Cyclophosphamide
3
Biopsy
3
130-nm albumin-bound paclitaxel
3
cemiplimab
2
avelumab
2
X-Rays
2
Tocopherols
2
Tiragolumab
2
Therapeutics
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Head and Neck Neoplasms
×
Metformin
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled